7, 2025 Journal of Obesity, A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity, May 10, 2024 KFF, Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford, Nov
Mol Cancer 23 , 90 (2024)
There was no heterogeneity detected in semaglutides renal, cardiovascular or mortality benefits, or in MACE and all-cause mortality, between those using or not using SGLT2 inhibitors (Mann et al, 2024)
20 After 52 weeks, steatohepatitis resolved without fibrosis progression in 44%, 56%, and 62% of participants receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg, respectively, compared to 10% in the placebo group
We believe access to effective weight loss treatment should not be hindered by cost